文献速递脊柱关节炎

古塞奇尤单抗对附着点炎的缓解及其与疾病负担的关系:两项3期银屑病关节炎研究1年结果

Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

在DISCOVER-1和DISCOVER-2两项3期研究中,古塞奇尤单抗(选择性IL-23p19亚基抑制剂)每4周或每8周给药在24周时缓解附着点炎的比例显著优于安慰剂(45%和50% vs 29%,校正P=0.0301)。52周时58%的古塞奇尤单抗随机化患者附着点炎缓解,且24周缓解者中42%在52周达到最小疾病活动度,而未缓解者仅17%。

要点

  • 古塞奇尤单抗每4周和每8周方案在24周缓解附着点炎均优于安慰剂。
  • 52周时58%古塞奇尤单抗随机化患者附着点炎缓解,缓解率持续上升。
  • 24周附着点炎缓解者52周达最小疾病活动度比例高于未缓解者。

核心结论

  • 古塞奇尤单抗治疗使银屑病关节炎患者24周附着点炎缓解比例高于安慰剂,且缓解率维持至1年。
  • 附着点炎缓解与52周最小疾病活动度达标率更高相关。

研究设计与样本

  • DISCOVER-1和DISCOVER-2两项3期研究,成人活动性银屑病关节炎患者随机1:1:1接受古塞奇尤单抗100mg每4周、古塞奇尤单抗100mg第0/4周后每8周或安慰剂至20周后古塞奇尤单抗100mg每4周。
  • 独立评估者采用利兹附着点炎指数(LEI,总分0-6)评估附着点炎,24周数据预设汇总分析,52周分析亦采用汇总数据。

主要发现

  • 1118例随机治疗患者中65%基线有附着点炎,这些患者肿胀和压痛关节数、全身炎症及身体功能受损数值上更重。
  • 24周时古塞奇尤单抗每4周和每8周组缓解已有附着点炎比例分别为45%和50%,安慰剂组29%(校正P=0.0301)。
  • 52周时58%古塞奇尤单抗随机化患者附着点炎缓解,基线轻度(LEI=1)缓解70-75%、中度(LEI=2)69-73%、重度(LEI=3-6)42-44%。
  • 24周附着点炎缓解的古塞奇尤单抗随机化患者中42%在52周达到最小疾病活动度,未缓解者仅17%。

关键数值与推荐

  • 附着点炎评估采用LEI,总分0-6。
  • 24周附着点炎缓解率:古塞奇尤单抗每4周45%、每8周50%、安慰剂29%,校正P=0.0301。

临床怎么用

  • 古塞奇尤单抗可用于改善银屑病关节炎患者的附着点炎,每4周或每8周方案均有效。
  • 附着点炎缓解可能预示更好的患者结局,治疗中应关注附着点炎评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To further characterize the effect of guselkumab, a selective IL-23p19-subunit inhibitor approved for PsA, on enthesitis and assess relationships between enthesitis resolution and patient status/outcomes. METHODS: Adults with active PsA despite standard therapies in the phase 3 DISCOVER-1 and DISCOVER-2 studies were randomized 1:1:1 to guselkumab 100 mg every 4 weeks (Q4W); guselkumab 100 mg at week 0, week 4, Q8W; or placebo through week 20 followed by guselkumab 100 mg Q4W. Independent assessors evaluated enthesitis using the Leeds Enthesitis Index (LEI; total score 0-6). Enthesitis findings through week 24 were pre-specified to be pooled across studies; post hoc and week 52 analyses also employed pooled data. RESULTS: Among 1118 randomized, treated patients in DISCOVER-1 and 2 who had ≥1 LEI site evaluated, 65% had enthesitis at baseline. These patients exhibited numerically more swollen and tender joints, systemic inflammation and impaired physical function than patients without enthesitis. Guselkumab Q4W and Q8W were superior to placebo in resolving pre-existing enthesitis at week 24 (45 and 50% vs 29%; both adjusted P = 0.0301). Enthesitis resolution rates continued to rise; 58% of guselkumab-randomized patients achieved resolution at week 52, including patients with mild (LEI = 1; 70-75%), moderate (LEI = 2; 69-73%) or severe (LEI = 3-6; 42-44%) enthesitis at baseline. Among guselkumab-randomized patients with resolved enthesitis at week 24, 42% achieved minimal disease activity at week 52, vs 17% of patients with unresolved enthesitis. CONCLUSION: Guselkumab resulted in higher proportions of PsA patients with resolved enthesitis by week 24, with maintenance of resolution rates through 1 year. As enthesitis confers greater disease burden, sustained resolution could portend better patient outcomes. CLINICAL TRIAL REGISTRATION: DISCOVER 1 (NCT03162796) and DISCOVER 2 (NCT03158285).

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. McGonagle D, McInnes IB, Deodhar A, et al. Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. Rheumatology (Oxford). 2021. PMID: 33822898. doi:10.1093/rheumatology/keab285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。